| Summary: | 碩士 === 中國醫藥學院 === 醫學研究所 === 90 === Malignant disease has been the leading cause of death in Taiwan for twenty years consecutively. There was 5000 to 6000 people died of hepatocellular carcinoma every year. Patients with primary hepatocellular carcinoma will died in few weeks to few months if they can not be treated intensively. At present, surgical resection still is the only modality for cure of the disease. Chemotherapy can be a palliative management once multiple hepatic recurrence or multiple distant metastases occurs postoperatively, or patient is not suitable for surgery due to other condition.
Paclitaxel has excellent therapeutic effects in breast cancer, ovarian cancer and non-small cell carcinoma of lung. It’s role in treatment of hepatocellular carcinoma is still undetermined.
In this experiment, paclitaxel is used to investigate its effect in cell cycle of hepatocellular carcinoma cell line (HA 22 T/VGH). The result showed paclitaxel arrested the cell cycle at G2/M phase. We also investigate the effect of paclitaxel to the regulation of cyclins and CDK in cell cycle and disclosed that high concentrated paclitaxel ( > 2.5 mM) suppressed the expression of cyclin B, D and CDK1, but had effect of over expression of cyclin A, E and CDK2.
The effect of paclitaxel to NAT was also investigated. We found that paclitaxel could inhibit NAT activity in cytosol of hepatocellular carcinoma cell line. It showed positive relation in drug concentration and duration of incubation.
In conclusion, paclitaxel seems could be a alternative modality in treatment of hepatocellular carcinoma. Its clinical benefits should be further evaluated.
|
|---|
